LIVZON PHARMA - Announcement on the progress of Livzon Pharmaceutical Group Co., Ltd.’s provision of guarantees for subsidiaries

does not make any representation about the accuracy or completeness of this announcement and expressly disclaims any liability arising out of or in connection with all or any part of this announcement.

We accept no liability for any loss caused by reliance on such content.

Overseas regulatory announcement

This announcement is made in accordance with Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

This is to set forth the "Livzon Pharmaceutical Group Co., Ltd." published on the website of the Shenzhen Stock Exchange Co., Ltd.’s Progress Announcement on Providing Guarantees for Subsidiaries” is for reference only.

By order of the board of directors

Livzon Pharmaceutical Group Co., Ltd. LivzonPharmaceuticalGroupInc.* company secretary Liu Ning

China, Zhuhai August 4, 2026

As at the date of this announcement, the executive directors of the Company are Mr. Liu Daping (President) and Mr. Tang Yanggang (Vice Chairman) and; the Company The non-executive directors of the company are Mr. Zhu Baoguo (Chairman), Mr. Lin Nanqi and Mr. Qiu Qingfeng; the employee director of the company is Ran Yong

Ms. Mei; and the independent non-executive directors of the Company are Mr. Luo Huiyuan, Ms. Cui Lijie, Ms. Wang Zhiyao and Ms. Kang Li.

*Identification only

Securities code: 000513, 01513 Securities abbreviation: Livzon Group, Livzon Pharmaceutical Announcement number: 2026-50

Livzon Pharmaceutical Group Co., Ltd.

Announcement on the progress of providing guarantees for subsidiaries

The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and there are no false records.

information, misleading statements or material omissions.

1. Overview of Guarantee

Livzon Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company" or "Livzon Group") in 2026

The 33rd meeting of the 11th Board of Directors was held on March 24, 2026 and will be held on May 29, 2026

The 2025 shareholders' meeting reviewed and approved the "Estimated Comprehensive Credit Grant and Guarantee Amount for Application in 2026" Proposal", the company plans to provide financing guarantees for subsidiaries within the scope of consolidated statements in 2026 and provide guarantees.

The form of guarantee is a joint liability guarantee, and the expected guarantee amount shall not exceed RMB 11,678,250,000 or its equivalent.

foreign currency. For details, please refer to the company’s announcement on cninfo.com (www.cninfo.com.cn) on March 25, 2026.

The disclosed "Announcement on the Estimated Comprehensive Credit Line Application and Guarantee Amount for 2026" (Announcement No.: 2026-

13).

2. Guarantee progress

In July 2026, the company entered into separate agreements with Zhuhai Branch of Bank of Communications Co., Ltd. (hereinafter referred to as "BoCom"). signed by Tongtong Bank") and Industrial and Commercial Bank of China Co., Ltd. Zhuhai Branch (hereinafter referred to as "ICBC")

The "Guarantee Contract" and "Maximum Guarantee Contract" were signed. The details are as follows:

(1) The company is a subsidiary of Livzon Group Livzon Pharmaceutical Factory (hereinafter referred to as "Livzon Pharmaceutical Factory") and the industrial

The maximum amount of guaranteed guarantee is provided for the main creditor's rights between commercial banks, and the maximum principal amount of the main creditor's rights guaranteed is

302 million yuan. Livzon Pharmaceutical Factory is a wholly-owned subsidiary of the company, and the reviewed guarantee amount is 2.797 billion yuan. The guarantee amount used before this guarantee was 805.00 million yuan. After this guarantee

The total guarantee limit used is RMB 1,107 million, and the remaining available guarantee limit is RMB 1,690 million.

(2) The company is a subsidiary of Sichuan Everbright Pharmaceutical Co., Ltd. (hereinafter referred to as "Sichuan Everbright") and

The maximum amount of guaranteed guarantee is provided for the main creditor's rights between banks, and the maximum principal amount of the main creditor's rights guaranteed is 100 million yuan. Sichuan Everbright is a wholly-owned subsidiary of the company, and the reviewed guarantee amount is 49,500.00

Ten thousand yuan, the guarantee amount used before this guarantee is 100 million yuan, and the total amount used after this guarantee

The guarantee limit is RMB 200 million, and the remaining available guarantee limit is RMB 295 million.

(3) The company is a subsidiary of Zhuhai Livzon Pharmaceutical Trading Co., Ltd. (hereinafter referred to as "Zhuhai Medical Trading") The maximum amount of guaranteed guarantee is provided for the main creditor's rights with Bank of Communications, and the maximum principal amount of the main creditor's rights guaranteed is

30 million yuan. Zhuhai Medical Trade is a wholly-owned subsidiary of the company, and the reviewed guarantee amount is 170,250.00

Ten thousand yuan, the guarantee amount used before this guarantee was 142.50 million yuan, and the total amount used after this guarantee

The guarantee limit is RMB 172.5 million, and the remaining available guarantee limit is RMB 1.53 billion.

(4) The company is its subsidiary Livzon Group (Ningxia) Pharmaceutical Co., Ltd. (hereinafter referred to as "Ningxia Company") The maximum amount of guaranteed guarantee is provided for the main creditor's rights with Bank of Communications, and the maximum principal amount of the main creditor's rights guaranteed is

120 million yuan. The company wholly owns the company through its holding subsidiary Livzon Group Xinbeijiang Pharmaceutical Co., Ltd.

It has 100.00% equity of Ningxia Company, and the reviewed guarantee amount is 680 million yuan. This guarantee has been

The guarantee limit used is 230 million yuan, and the total guarantee limit used after this guarantee is 35,000.00

Ten thousand yuan, and the remaining available guarantee amount is 330 million yuan. (5) The company is a subsidiary of Livzon Group Xinbeijiang Pharmaceutical Co., Ltd. (hereinafter referred to as "Xinbeijiang

Pharmaceuticals") and Bank of Communications provide the highest amount of guarantee for the main creditor's rights, and the guaranteed principal of the main creditor's rights is the largest

The high amount is NT$40 million. The company’s shareholding ratio in Xinbeijiang Pharmaceutical is 87.14%, and the guarantee after review

The limit is RMB 1,104.75 million. The guarantee limit that has been used before this guarantee is RMB 174.75 million. This time

The total guarantee amount used after the guarantee is 214.75 million yuan, and the remaining available guarantee amount is 890.00 million yuan. Yuan.

(6) The company is its subsidiary Jiaozuo Livzon Synthetic Pharmaceutical Co., Ltd. (hereinafter referred to as "Jiaozuo Synthetic")

The maximum amount of guaranteed guarantee is provided for the main creditor's rights with Bank of Communications, and the maximum principal amount of the main creditor's rights guaranteed is

60 million yuan. The company holds Jiaozuo through its wholly-owned subsidiary Zhuhai Free Trade Zone Livzon Synthetic Pharmaceutical Co., Ltd.

Synthetic 75% of the equity, the reviewed guarantee amount is 650 million yuan, the guarantee that has been used before this guarantee The limit is 230 million yuan. The total guarantee limit used after this guarantee is 290 million yuan, and the remaining

The available guarantee amount is 360 million yuan.

3. Basic information of the guaranteed person

Please see Appendix 1 and Appendix 2 for the basic information and main financial indicators of the guaranteed party.

4. Main contents of the guarantee agreement

The main contents of the guarantee agreement signed between the company and the bank are shown in the following table:

Guaranteed amount Preface: Signing of the agreement to guarantee the main creditor's rights. Is it relevant? Secured party (RMB Guarantee period Guarantee type Counter guarantee situation No. Period Bank Joint Guarantee Ten thousand yuan) Loans under autonomous contracts July 2026 Loan term or precious metal lease joint and several liability 1 Livzon Pharmaceutical Factory 30,200.00 1 to 2029 Industrial and Commercial Bank of China None No The day after the loan period expires June 30 Three years from now July 2026 joint and several liability 2 Sichuan Everbright 10,000.00 15th to 2027 Bank of Communications None No protect July 15 From July 2026, the debt payment period joint and several liability 3 Zhuhai Medical Trade 3,000.00 16th to the expiration date of 2029 (or debt Bank of Communications None No protect On May 15, the right holder advanced the payment From July 2026) to all main combinations joint and several liability 4 Ningxia Company 12,000.00 17th to 2027 The last due date under the same item is Bank of Communications None No protect On July 17, the main debt performance deadline expires The date of expiration in July 2026 (or the creditor and the guaranteed party joint and several liability 5 Xinbeijiang Pharmaceutical 4,000.00 From 16th to 2027 (the date of advance payment) Bank of Communications Other shareholders have No protect September 7, 2020, three years from now. Counter guarantee provided. July 2026 joint and several liability 6 Jiaozuo Hesheng 6,000.00 15th to 2027 Bank of Communications None No protect July 15 5. Cumulative number of external guarantees and number of overdue guarantees As of July 31, 2026, the company's total guarantee amount is 13,778.25 million yuan; the company The actual balance of external guarantees is RMB 1,653,656,500, accounting for 10% of the company’s most recent audited balance attributable to shareholders of the parent company. The proportion of net assets (13,888,350,600 yuan) is 11.91%, all of which are guarantees provided by the company to its subsidiaries. The company has no guarantees for units outside the consolidated statements, no guarantees for overdue debts, and no guarantees involving litigation. Guarantee, there is no situation such as loss should be borne due to a judgment against the guarantee. 6. Documents available for inspection (1) The "Maximum Guarantee Contract" signed by the company and Industrial and Commercial Bank of China to provide guarantee for Livzon Pharmaceutical Factory; (2) The "Guarantee Contract" signed by the company and Bank of Communications to provide guarantee for Sichuan Everbright; (3) The "Guarantee Contract" signed by the company and Bank of Communications to provide guarantee for Zhuhai Medical Trade; (4) The "Guarantee Contract" signed by the company and Bank of Communications to provide guarantee for Xinbeijiang Pharmaceutical;

(5) The "Guarantee Contract" signed by the company and Bank of Communications to provide guarantee for the Ningxia Company;

(6) The "Guarantee Contract" signed by the company and Bank of Communications to provide guarantee for Jiaozuo Hesheng.

Announcement is hereby made.

Board of Directors of Livzon Pharmaceutical Group Co., Ltd.

August 5, 2026

Schedule 1:

Basic information table of the guaranteed person

Until 2026 Is the registered capital a loss? July 31, 2018 Preface Guaranteed Party Establishment Date Legal Representative Relationship with the Company Registration location (RMB) Business scope Date of execution of letter Actual guarantee No. Name Period Person Department Ten thousand yuan) Person Balance (Renminbi (10,000 yuan) Licensed items: pharmaceutical production (excluding steaming, frying, broiling, calcining and other processing techniques of traditional Chinese medicine pieces) application of technology and the production of confidential prescription products of proprietary Chinese medicines); commissioned production of pharmaceuticals; pharmaceuticals Import and export; inspection and testing services; drug retail; drug wholesale; indoor environment testing; Veterinary drug production; veterinary drug operation. (Projects that require approval according to law must be approved by relevant departments Business activities can only be carried out after Certificate shall prevail) General projects: technical services, technical development, technical consulting, technical exchange Stream, technology transfer, technology promotion; bio-based material technology research and development; biochemical products 1989 Jinwan, Zhuhai Technology research and development; medical research and experimental development (except human stem cells, genetic diagnosis and treatment Livzon Pharmaceutical 1 November 26 Xu Xiao, Chuangye North Road, District 45,000.00 Development and application of therapeutic technology); Internet sales (except for the sale of goods requiring licenses); Wholly-owned subsidiary No 23,011.40 factory Day 38 Production of chemical products (excluding licensed chemical products); sales of special chemical products (not Contains hazardous chemicals); engineering and technology research and experimental development (except human stem cells, Development and application of genetic diagnosis and treatment technology, China’s rare and unique precious and excellent products species); manufacturing of special chemical products (excluding hazardous chemicals); sales of chemical products (not including licensed chemical products); import and export of goods; manufacturing of basic chemical raw materials (excluding hazardous manufacturing of hazardous chemicals and other licensed chemicals); research and development of bio-based material polymerization technology; Production of traditional Chinese medicine extracts. (Except for projects that require approval according to law, a business license must be obtained in accordance with the law. Carry out business activities independently) 2 Sichuan Everbright 1993 Chengdu, Sichuan Province Cai Xinfu 14,900.00 Licensed projects: pharmaceutical production; pharmaceutical wholesale; pharmaceutical retail; pharmaceutical commissioned production; insurance wholly-owned subsidiary No 1,485.30

December 1, Pengzhou City Dongjian Food Production. (Projects that require approval according to law can only be launched after approval by relevant departments. Section 2 of the Third Ring Road will carry out business activities, and specific business projects shall be subject to the approval documents or licenses of relevant departments)

No. 233 General items: sales of health food (prepackaged); acquisition of Chinese herbal medicine; Internet sales (Except for selling goods that require licensing); technical services, technology development, technical consulting, Technology exchange, technology transfer, technology promotion; medical research and experimental development (except human body Stem cell, gene diagnosis and treatment technology development and application). (Except where approval is required by law In addition to projects, we can independently carry out business activities in accordance with the law with a business license) (involving national regulations

Except for implementation of special access management measures) Zhuhai Jinwan District Chuangye North Road Licensed projects: pharmaceutical wholesale; pharmaceutical import and export. (Projects that require approval according to law shall be No. 38 Livzon Works can only carry out business activities after approval from relevant departments. Specific business projects are subject to approval by relevant departments. June 1991 3 Zhuhai Medical Trade Industrial Park Administrative Building Zheng Tao 6,000.00 Approval documents or licenses shall prevail) General items: import and export of goods; sales of chemical products Wholly owned subsidiary No 100.00 March 22 513, 5th Floor, (excluding licensed chemical products); sales of special chemical products (excluding hazardous chemicals). 515, 516, 517 (Except for projects that require approval according to law, business activities can be carried out independently with a business license and in accordance with the law) room Licensed projects: food additive production; feed additive production; veterinary drug production; veterinary drugs Business; pharmaceutical production. (Projects that require approval according to law must be approved by relevant departments. Ningxia Pingluo Gong Business activities can be carried out, and specific business projects must be approved by relevant departments or licenses. The company's holding subsidiary 2011 8 Industrial Park 301 Province 4 Ningxia Company Qin Gang 20,000.00 (subject to 20,000.00) General items: food additive sales; import and export of goods; import and export agency; subsidiary of the company No 18,836.04 On the 17th of the month, Daonan side head stone Technology import and export; feed additive sales; non-residential real estate leasing; machinery and equipment leasing company west side of highway leasing; manufacturing of basic chemical raw materials (excluding the manufacturing of hazardous chemicals and other licensed chemicals). (Except for projects that require approval according to law, business activities can be carried out independently with a business license and in accordance with the law) Licensed business items: production of pharmaceuticals (for details on scope, please refer to the "Pharmaceutical Production of the People's Republic of China") Qingyuan, Guangdong Province Xinbeijiang Manufacturing License in 1993), the production of veterinary drugs (for details, please see the "Veterinary Drug Production of the People's Republic of China") 5 City Renmin 1st Road Yang Tongsheng 23,988.77 Holding subsidiary No 2,568.28 Pharmaceutical production license on March 28th); general business items: manufacturing of pharmaceutical intermediates, chemical raw materials and (One photo, multiple addresses) The manufacturing of products, the manufacturing of feed additives and food additives, the operation of this enterprise and the

Export business of self-produced products and related technologies of corporate members, pharmaceutical-related products and Research and development, technical services, technology transfer, translation services, and information services for health-related industrial products

Information technology services, training services, raw and auxiliary materials, machinery and equipment required for production and scientific research, Import business of instruments, spare parts and related technologies. (Items that require approval according to law business activities can be carried out only after approval by relevant departments) General projects: production of chemical products (excluding licensed chemical products); sales of chemical products sales (excluding licensed chemical products); manufacturing of special chemical products (excluding hazardous chemicals)

products); sales of specialized chemical products (excluding hazardous chemicals); medical research and testing Development; manufacturing of basic chemical raw materials (excluding hazardous chemicals and other licensed chemicals) Made in Macun, Jiaozuo City); sales of food additives; sales of feed additives; technical services, technology development, the company's wholly-owned subsidiary 2009 7 6 Jiaozuo Hehe District Wanfang Industry Zheng Tao 15,520.00 Technical consultation, technology exchange, technology transfer, technology promotion (except for subsidiaries of the company that require approval according to law No 16,556.48 month 10 In addition to the park project, the company can independently carry out business activities in accordance with the law with a business license) Licensed project: Pharmaceutical Production Department production; import and export of pharmaceuticals; commissioned pharmaceutical production; veterinary drug operations; veterinary drug production; medicinal auxiliary products Production of raw materials; sales of pharmaceutical excipients; production of food additives; production of feed additives (according to For projects that require approval by law, business activities can only be carried out after approval by relevant departments. Specifically, Business projects are subject to approval documents or licenses from relevant departments)

Schedule 2: Main financial indicators of the guaranteed party

Unit: RMB 10,000 Preface Name of the guaranteed party March 31, 2026 (unaudited) January-March 2026 (unaudited) December 31, 2025 (audited) 2025 (audited) Title Total assets Total liabilities Net assets Operating income Net profit Total assets Total liabilities Net assets Operating income Net profit

1 Livzon Pharmaceutical Factory 641,958.50 123,577.98 518,380.52 68,979.20 37,094.33 606,490.29 125,204.09 481,286.19 327,875.16 86,609.12 2 Sichuan Everbright 182,978.44 42,402.26 140,576.18 9,206.36 900.36 185,479.66 45,803.84 139,675.82 51,150.56 8,138.25 3 Zhuhai Medical Trade 19,907.23 8,701.58 11,205.65 6,624.61 23.14 23,533.98 12,351.47 11,182.51 29,908.14 11.14 4 Ningxia Company 131,949.44 36,983.84 94,965.60 21,992.79 4,360.54 125,129.31 34,524.25 90,605.06 106,029.23 19,099.72

5 Xinbeijiang Pharmaceutical 448,196.79 81,855.65 318,699.23 61,531.49 14,232.51 430,576.17 81,595.64 304,466.25 249,914.79 54,442.44 6 Jiaozuo Synthesis 46,720.36 28,887.07 17,833.29 9,221.30 92.74 41,932.12 28,711.57 13,220.55 38,703.56 1,736.38